Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Biotech
FDA rejects Replimune’s melanoma prospect for second time
Even with additional data and a new team of reviewers, the FDA still found fault with the trials for Replimune's oncolytic virus.
Darren Incorvaia
Apr 10, 2026 1:56pm
Fierce Biotech Fundraising Tracker '26: Vivatides; Life Bio & more
Apr 10, 2026 10:00am
How ctDNA is redefining MRD monitoring in hematologic cancers
Brought to you by
Allucent
Former TreeFrog CEO leaps to Orano Med—Chutes & Ladders
Apr 10, 2026 8:30am
Carl Sailer on AI, market trends, and strategic planning in biotech
Brought to you by
Syneos Health
'Can it deliver?': Why Big Pharma has entered the quantum realm
Apr 10, 2026 7:20am
